References
- Goldberg DS , McGeeSJ. Pain as a global public health priority. BMC Public Health11, 700 (2011).
- Treede RD , RiefW , BarkeAet al. A classification of chronic pain for ICD-11. Pain156(6), 1003–1007 (2015).
- Nicholson B . Responsible prescribing of opioids for the management of chronic pain. Drugs63(1), 17–32 (2003).
- Singh A , ZaiC , MohiuddinAG , KennedyJL. The pharmacogenetics of opioid treatment for pain management. J. Psychopharmacol.34(11), 1200–1209 (2020).
- WHO . Opioid overdose. https://apps.who.int/iris/handle/10665/64993?locale-attribute=es&
- Corli O , DamiaG , GalliF , VerrastroC , BrogginiM. Lack of efficacy: when opioids do not achieve analgesia from the beginning of treatment in cancer patients. Cancer Manag. Res.11 (2019).
- Smith HS . Opioid metabolism. Mayo Clin. Proc.84(7), 613–624 (2009).
- Cregg R , RussoG , GubbayA , BranfordR , SatoH. Pharmacogenetics of analgesic drugs. Br. J. Pain7(4), 189–208 (2013).
- Matic M , DeWildt SN , TibboelD , Van SchaikRHN. Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin. Chem.63(7), 1204–1213 (2017).
- Ruaño G , KostJA. Fundamental considerations for genetically-guided pain management with opioids based on cyp2d6 and oprm1 polymorphisms. Pain Physician21(6), E611–E621 (2018).
- Caudle KE , SangkuhlK , Whirl-CarrilloMet al. Standardizing CYP2D6 genotype to phenotype translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci.13(1), 116–124 (2020).
- PharmGKB . Gene-specific information tables for CYP2D6. https://www.pharmgkb.org/page/cyp2d6RefMaterials
- Crews KR , GaedigkA , DunnenbergerHMet al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update. Clin. Pharmacol. Ther.95(4), 376–382 (2014).
- Gaedigk A , SangkuhlK , Whirl-CarrilloM , KleinT , StevenLeeder J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med.19(1), 69–76 (2017).
- Drewes AM , JensenRD , NielsenLMet al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br. J. Clin. Pharmacol.75(1), 60–78 (2013).
- Yu Z , WenL , ShenX , ZhangH. Effects of the OPRM1 A118G polymorphism (rs1799971) on opioid analgesia in cancer pain: a systematic review and meta-analysis. Clin. J. Pain35(1), 77–86 (2019).
- Hu B , ZhangX , XuGet al. Association between COMT polymorphism Val158Met and opioid consumption in patients with postoperative pain: a meta-analysis. NeuroSignals26(1), 11–21 (2019).
- Hwang IC , ParkJY , MyungSK , AhnHY , FukudaKI , LiaoQ. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. Anesthesiology121(4), 825–834 (2014).
- Henker RA , LewisA , DaiFet al. The associations between OPRM1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol. Res. Nurs.15(3), 309–317 (2013).
- Cavallari LH , Van DriestSL , ProwsCAet al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet. Med.21(10), 2255–2263 (2019).
- Frigon MP , BlackburnMÈ , Dubois-BouchardC , GagnonAL , TardifS , TremblayK. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics20(8), 589–598 (2019).
- Crews K , MonteA , HuddartR. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clin. Pharmacol. Ther. (2020). https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2149
- Cochrane . Cochrane Handbook for Systematic Reviews of Interventions. https://training.cochrane.org/handbook/current
- Moher D , LiberatiA , TetzlaffJet al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med.6(7), e123–130 (2009).
- Liberati A , AltmanDG , TetzlaffJet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med.6(7), e1000100 (2009).
- Rodriguez Cairoli F . Is opioid therapy guided by pharmacogenetics safer and more efficacious than usual opioid treatment for pain management?. PROSPERO (2019). https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=150313
- Covidence . Covidence. https://www.covidence.org
- Cochrane . RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
- Cochrane . ROBINS-I tool. https://methods.cochrane.org/methods-cochrane/robins-i-tool
- NCT03455751 . Precision pain management for major abdominal surgery in colorectal surgery. (2018). https://clinicaltrials.gov/show/NCT03455751
- NCT04445792 . A depression and opioid pragmatic trial in pharmacogenetics (DCRI coordinating center) (ADOPT PGx). (2020). https://clinicaltrials.gov/ct2/show/NCT04445792
- NCT03924557 . Genotype-guided supportive care in symptom treatment of cancer patients. (2019). ClinicalTrials.gov
- Truong TM , ApfelbaumJ , ShahulSet al. The ImPreSS Trial: implementation of point-of-care pharmacogenomic decision support in perioperative care. Clin. Pharmacol. Ther.106(6), 1179–1183 (2019).
- NCT02605343 . Prospective observational clinical study to evaluate patient outcomes following pharmacogenetic testing of patients undergoing elective surgical procedures. https://clinicaltrials.gov/ct2/show/NCT02605343
- NCT02599870 . Clinical study to evaluate clinical impact of PGx-guided treatment for patients undergoing elective spinal surgical procedures. (2015). https://clinicaltrials.gov/ct2/show/NCT02599870
- Moretti ME , LatoDF , BergerH , KorenG , ItoS , UngarWJ. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. Pharmacogenomics J.18(3), 391–397 (2018).
- NCT01731873 . Patient controlled analgesia pharmacogenetic study. (2012). https://clinicaltrials.gov/ct2/show/NCT01731873
- AC B , DK , BABet al. Impact of preemptive CYP2D6 genotyping: results from an institutional pharmacogenomics program. Clin. Pharmacol. Ther.103, S26 (2018).
- Fulton CR , ZangY , DestaZet al. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics20(6), 397–408 (2019).
- Sharma M , KantorovichS , LeeCet al. An observational study of the impact of genetic testing for pain perception in the clinical management of chronic non-cancer pain. J. Psychiatr. Res.65–72 (2017).
- Palada V , KaunistoMA , KalsoE. Genetics and genomics in postoperative pain and analgesia. Curr. Opin. Anaesthesiol.31(5), 569–574 (2018).
- Yang GS , BarnesNM , LyonDE , DorseySG. Genetic variants associated with cancer pain and response to opioid analgesics: implications for precision pain management. Semin. Oncol. Nurs.35(3), 291–299 (2019).
- Smith DM , WeitzelKW , CavallariLH , ElseyAR , SchmidtSO. Clinical application of pharmacogenetics in pain management. Per. Med.15(2), 117–126 (2018).
- Lloyd RA , HothamE , HallC , WilliamsM , SuppiahV. Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanyl. Pain Med. (USA)18(12), 2369–2387 (2017).
- Dorfman R , LondonZ , MetiasM , KabakchievB , MukerjeeG , MoserA. Individualized medication management in ontario long-term care clinical impact on management of depression, pain, and dementia. J. Am. Med. Dir. Assoc.21(6), 823–829 (2020).
- Mosley SA , HicksJK , PortmanDGet al. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp. Clin. Trials.68 (2018).
- Fenech A , PortmanD , ChangY , SmithJ , DonovanK. Pilot study to assess the feasibility and acceptability of pharmacogenomics research for pain control in palliative care. Psychooncology26, 71 (2017).
- Smith DM , WeitzelKW , ElseyARet al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med.21(8), 1842–1850 (2019).
- Senagore AJ , ChampagneBJ , DosokeyEet al. Pharmacogenetics-guided analgesics in major abdominal surgery: further benefits within an enhanced recovery protocol. Am. J. Surg.213(3), 467–472 (2017).
- Thomas CD , ParvataneniHK , GrayCFet al. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet. Med.621–628 (2021).
- Patel JN , BoselliD , HamadehISet al. Pain management using clinical pharmacy assessments with and without pharmacogenomics in an Oncology Palliative Medicine Clinic. JCO Oncol. Pract.16(2), e166–e174 (2020).
- Hamilton WG , GargiuloJM , ParksNL. Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty: a randomized pilot study. Bone Jt J.102-B(6), 73–78 (2020).
- Baber M , BapatP , NicholG , KorenG. The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review. Pharmacogenomics17(1), 75–93 (2016).
- Ahmed S , ChoudhryZ , BhattiJA. Impact of genetic polymorphisms on opioid misuse: a scoping review. Pharmacogenomics20(9), 685–703 (2019).
- Wu SB , CaiLN , YangXHet al. Impact of CYP2D6 polymorphisms on postoperative fentanyl analgesia in gastric cancer patients. Genet. Test. Mol. Biomarkers19(5), 248–252 (2015).
- Yamamoto PA , ConchonCosta AC , LaurettiGR , DeMoraes NV. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice. Pharmacogenomics20(13), 971–982 (2019).
- Clinicaltrial.gov . Comparison of standard opioid prescription versus prescription guided by pharmacogenetic analysis in patients with non-cancerous chronic pain. (2018). https://www.clinicaltrials.gov/ct2/show/NCT03498014
- Kheiri B , OsmanM , AbdallaAet al. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: a meta-analysis of randomized clinical trials. Catheter. Cardiovasc. Interv.93(7), 1246–1252 (2019).